Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barbara Weber

Showing results (61-70 of 70) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 70 results.
Breast Cancer Research : BCR|February 11, 2017
Erratum to: Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancerZhi Hu, Jian-Hua Mao, Christina Curtis, et al.
International Journal of Cancer|June 30, 2005
Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriersCarey A Cullinane, Jan Lubinski, Susan L Neuhausen, et al.
Breast Cancer Research : BCR|March 28, 2006
Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriersEitan Friedman, Joanne Kotsopoulos, Jan Lubinski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2004
Pathology of ovarian cancers in BRCA1 and BRCA2 carriersSunil R Lakhani, Sanjiv Manek, Frederique Penault-Llorca, et al.
Journal of the National Cancer Institute|December 5, 2002
Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriersSteven A Narod, Marie-Pierre Dubé, Jan Klijn, et al.
Nature Genetics|April 23, 2002
Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutationsHanne Meijers-Heijboer, Ans van den Ouweland, Jan Klijn, et al.
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz|February 20, 2020
[Measuring physical fitness in the German National Cohort-methods, quality assurance, and first descriptive results]Alexander Kluttig, Johannes Zschocke, Johannes Haerting, et al.
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz|July 11, 2025
Alexander Kluttig, Johannes Zschocke, Johannes Haerting, et al.
Nature Communications|January 16, 2019
Author Correction: Characterization of Nigerian breast cancer reveals prevalent homologous recombination deficiency and aggressive molecular featuresJason J Pitt, Markus Riester, Yonglan Zheng, et al.
Nature Communications|October 18, 2018
Characterization of Nigerian breast cancer reveals prevalent homologous recombination deficiency and aggressive molecular featuresJason J Pitt, Markus Riester, Yonglan Zheng, et al.
Pageof 7

Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
Breast Cancer Research : BCR|February 11, 2017
Erratum to: Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancerZhi Hu, Jian-Hua Mao, Christina Curtis, et al.
International Journal of Cancer|June 30, 2005
Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriersCarey A Cullinane, Jan Lubinski, Susan L Neuhausen, et al.
Breast Cancer Research : BCR|March 28, 2006
Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriersEitan Friedman, Joanne Kotsopoulos, Jan Lubinski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2004
Pathology of ovarian cancers in BRCA1 and BRCA2 carriersSunil R Lakhani, Sanjiv Manek, Frederique Penault-Llorca, et al.
Journal of the National Cancer Institute|December 5, 2002
Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriersSteven A Narod, Marie-Pierre Dubé, Jan Klijn, et al.
Nature Genetics|April 23, 2002
Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutationsHanne Meijers-Heijboer, Ans van den Ouweland, Jan Klijn, et al.
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz|February 20, 2020
[Measuring physical fitness in the German National Cohort-methods, quality assurance, and first descriptive results]Alexander Kluttig, Johannes Zschocke, Johannes Haerting, et al.
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz|July 11, 2025
Alexander Kluttig, Johannes Zschocke, Johannes Haerting, et al.
Nature Communications|January 16, 2019
Author Correction: Characterization of Nigerian breast cancer reveals prevalent homologous recombination deficiency and aggressive molecular featuresJason J Pitt, Markus Riester, Yonglan Zheng, et al.
Nature Communications|October 18, 2018
Characterization of Nigerian breast cancer reveals prevalent homologous recombination deficiency and aggressive molecular featuresJason J Pitt, Markus Riester, Yonglan Zheng, et al.
Pageof 7